Bonus Biogroup Ltd.
OTC: BBIXF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- Shai Meretzki
- Employees
- 42
- Headquarters
- Haifa, Israel
- IPO year
- 2019
- Market cap
- $128.5M
- Website
- https://bonus-bio.com
Loading BBIXF…
Loading profile data…Frequently asked questions about BBIXF
What does Bonus Biogroup Ltd. (BBIXF) do?
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as...
Where does BBIXF trade?
Bonus Biogroup Ltd. (BBIXF) trades on the Other OTC.
What sector is BBIXF in?
Bonus Biogroup Ltd. (BBIXF) operates in the Healthcare sector, specifically in the Medical - Specialties industry.
Who is the CEO of Bonus Biogroup Ltd.?
Shai Meretzki is the chief executive officer of Bonus Biogroup Ltd. (BBIXF).
Where is Bonus Biogroup Ltd. headquartered?
Bonus Biogroup Ltd. is headquartered in Israel.
Does BBIXF pay a dividend?
Bonus Biogroup Ltd. (BBIXF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BBIXF go public?
Bonus Biogroup Ltd. (BBIXF) completed its initial public offering in 2019.